Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...
The Daily Overview on MSN
Nvidia teams with biotech giants to supercharge AI drug discovery
Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...
Explore the impact of drug discovery automation in 2026, addressing complexity and improving decision-making across ...
2026 is highlighted as the year of the singularity with Elon Musk warning of underestimated impacts; conversations with him ...
CrowdStrike's 2025 data shows attackers breach AI systems in 51 seconds. Field CISOs reveal how inference security platforms ...
Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...
The Chosun Ilbo on MSN
Tesla CEO Elon Musk predicts humanoid robots to replace surgeons in 3 years
Telsa CEO Elon Musk stated that humanoid robots will replace surgeons within three years, declaring, “Going to medical school is meaningless.” Musk made the remarks on the 8th while appearing on ...
Nkembuh, N. (2026) Symbiotic Communication Systems: Examining the Co-Evolution of Human-AI Communication Patterns in the ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
The market is rapidly transitioning from episodic diagnostics to continuous health monitoring. By 2035, the integration of ...
MIT’s Recursive Language Models rethink AI memory by treating documents like searchable environments, enabling models to ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback